Navigation Links
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
Date:10/8/2007

ed and the incidence of adverse events in ceftobiprole-treated patients was similar to those observed in the vancomycin plus ceftazidime-treated patients.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is part of Johnson & Johnson, the world's most broadly-based producer of healthcare products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

[This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.]

For more information
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
8. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
9. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
10. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
11. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
(Date:8/30/2014)... 30, 2014 Seniors Guide, the comprehensive guide ... focus on Alzheimer’s Disease, Dementia, and Memory Loss . ... public of being diagnosed with the Alzheimer’s, inspired Seniors Guide ... Be Me”. The movie, out on October 14, 2014, ... his diagnosis of the disease – which inspires a final ...
(Date:8/30/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... lead extraction (TLE) is clinically successful in more than ... Lead Extraction ConTRolled (ELECTRa) registry presented for the first ... Grazia Bongiorni, chair of the registry,s executive committee. , ... devices (CIED) implant procedures has grown in recent years. ... increased and leads are often the cause. TLE is ...
(Date:8/30/2014)... The new review published by Daily Gossip reveals ... Brimeyer, who wanted to make her guide accessible to sufferers ... now easy to find in the form of an eBook, ... author of the new method shares all her tips and ... in its review that the leaky gut syndrome can be ...
Breaking Medicine News(10 mins):Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2
... 7 MQ Associates, Inc.,("MedQuest"), a leading national provider ... third quarter and nine months ended,September 30, 2007. ... 2007, representing,a decrease of $8.1 million, or 11.9%, from ... Net revenue was $186.5 million for the nine months,ended ...
... for retinopathy laser treatment, study finds , WEDNESDAY, Nov. ... diabetes, the drug fenofibrate reduces the need for laser ... loss and blindness among working-age adults worldwide. , Australian ... ages 50-75, who received either 200 milligrams per day ...
... 7 MED3OOO, Inc., a national healthcare,management ... Molina,Healthcare of California to provide Revenue Cycle ... communications technology, and,coding services. Molina Healthcare ... managed,healthcare companies serving patients who have traditionally ...
... BURLINGTON, Mass., Nov. 7 LeMaitre Vascular,Inc. (Nasdaq: ... medical,devices and implants for the treatment of peripheral ... Adams inaugural Cardiovascular,Conference on Tuesday, November 13, 2007, ... David B. Roberts, President of LeMaitre Vascular, ...
... Changes reflect company,s focus on growth and value ... Technologies, Inc. ("EAU",or "Company") (OTC Bulletin Board: EAUI), ... Technology" to numerous industries,including food processing, agriculture, dairy ... help the organization,better meet the needs of its ...
... cholesterol-lowering drug appears to disrupt sleep patterns of some ... Sessions 2007. , The findings are significant because sleep ... adverse health consequences, such as promoting weight gain and ... the study and an associate professor of medicine and ...
Cached Medicine News:Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 2Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 3Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 4Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 5Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 6Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 7Health News:Diabetes Drug Helps Protect Patients' Eyes 2Health News:Molina Medical Group Selects MED3OOO 2Health News:EAU Technologies Announces New Chairman of the Board and Board Leadership 2Health News:EAU Technologies Announces New Chairman of the Board and Board Leadership 3Health News:EAU Technologies Announces New Chairman of the Board and Board Leadership 4Health News:Cholesterol-lowering drug linked to sleep disruptions 2
... cannula with 30 gauge, 4.76 mm tip is ... Cannula is attached to a luer lock high ... inch long), for use with high viscosity substances. ... using visco elastic materials. Flattened, angled tip of ...
20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
The moist air humidifying chamber is designed for the infusion of humidified air during phakic fluid air exchange. Sterile single-use. 10 per box. Most popular size or model....
Medicine Products: